As part of one of the best developmental therapeutics programs in the country, our clinical pharmacologists conduct more clinical trials than any pediatric cancer center in the nation and are leaders in the development of new chemotherapy treatments for pediatric cancer.
Texas Children’s clinical pharmacologists have developed a number of new anti-cancer agents currently undergoing clinical trials within the Cancer Center. Many of the clinical trials performed at Texas Children’s Cancer Center are supported in part by the hospital’s National Institutes of Health-supported Clinical Research Center (CRC).
Texas Children’s Cancer Center pharmacologists received a grant of nearly $1.5 million from the National Institute of Child Health and Human Development to fund the Texas Children’s Pediatric Pharmacology Research Unit (PPRU). This unit conducts studies to assure the safety of drug treatments in children.
Featured Phase I and Phase II Clinical Trials
PBTC-033 — A Phase I/II Study of ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas
Administration of rapidly generated LMP, BARF1 and EBNA1 specific cytotoxic T-lymphocytes to patients with EBV-positive lymphoma
Vaccination to enhance the antitumor activity of GD2 chimeric antigen receptor expression VZV-specific T cells in subjects with advanced sarcomas
Administration of HER2 chimeric antigen receptor expression cells for subjects with advanced sarcoma